Biotech
KaliVir’s VET3-TGI Regimens Show 71% Response Rate in Advanced Skin Cancers in Early Trial
Preliminary data from intratumoral VET3-TGI presented in oral session at SITC 2026; abstract recognized among SITC’s top 150 abstracts Responses o...
November 10, 2026 | News
Differentia Bio Reports Clinical Support for AI-Predicted Treatment Strategies in IgG4-Related Disease
From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharma...
November 05, 2026 | News
Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...
November 05, 2026 | News
APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now
Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...
November 05, 2026 | Analysis
Nuance Pharma Doses First Patient in China Phase III Trial of Actair for House Dust Mite Allergy
Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of ho...
November 03, 2026 | News
Ono Pharma’s ONO-1110 Shows Promising Pain Relief Signals Across Three Phase II Studies
Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
October 30, 2026 | News
EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...
October 28, 2026 | News
Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...
October 22, 2026 | News
Metabolon Launches AI-Enabled Splash & Ripple to Accelerate Metabolomics-Driven Drug Discovery
New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpr...
October 22, 2026 | News
China’s Hiteck Biological Pharma Licenses Next-Generation Eye Therapy to Visara for Global Development
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has entered into an exclusive license agreement (the "License Agreement") with Visara, Inc...
October 15, 2026 | News
GenScript and NVIDIA Launch Global PitchFest to Accelerate AI-Driven Drug Discovery Startups
GenScript Biotech Corporation announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying arti...
October 12, 2026 | News
Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...
October 12, 2026 | News
Biotech Failures 2026: What Did Not Happen in APAC Biopharma
Approvals get counted, deals get ranked, listings get priced. The other half of the year, the programmes that stopped, the applications that came back, the...
October 02, 2026 | Analysis
Thermo Fisher Launches CHO-K1 Media Panel to Boost Biologics Production
Thermo Fisher Scientific, the world leader in serving science, announced the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed me...
September 24, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
